1.35 0.04 (3.05%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.77 ![]() |
1-year : | 1.98 ![]() |
Resists | First : | 1.51 ![]() |
Second : | 1.7 ![]() |
Pivot price | 1.35 ![]() |
|||
Supports | First : | 1.22 | Second : | 1.01 |
MAs | MA(5) : | 1.3 | MA(20) : | 1.39 ![]() |
MA(100) : | 1.84 ![]() |
MA(250) : | 2.74 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 27.6 ![]() |
D(3) : | 19.8 ![]() |
RSI | RSI(14): 40.7 ![]() |
|||
52-week | High : | 8.32 | Low : | 1.22 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRBU ] has closed above bottom band by 46.6%. Bollinger Bands are 61.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.42 - 1.43 | 1.43 - 1.43 |
Low: | 1.31 - 1.32 | 1.32 - 1.32 |
Close: | 1.34 - 1.35 | 1.35 - 1.36 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Fri, 14 Feb 2025
Caribou Biosciences, Inc. Investors: Please contact the - GlobeNewswire
Fri, 14 Feb 2025
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) - February 24, 2025 Deadline to Join - Contact Levi & Korsinsky - PR Newswire
Thu, 13 Feb 2025
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Mon, 10 Feb 2025
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 91 (M) |
Held by Insiders | 8.158e+007 (%) |
Held by Institutions | 10 (%) |
Shares Short | 9,800 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.578e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 666.9 % |
Return on Equity (ttm) | -25.2 % |
Qtrly Rev. Growth | 1.147e+007 % |
Gross Profit (p.s.) | -40.45 |
Sales Per Share | -19.3 |
EBITDA (p.s.) | -5.28717e+007 |
Qtrly Earnings Growth | -1.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -124 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.07 |
Price to Cash Flow | 0.98 |
Dividend | 0 |
Forward Dividend | 1.08e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |